Plus Therapeutics, Inc. (NASDAQ:PSTV) Short Interest Update

Plus Therapeutics, Inc. (NASDAQ:PSTV) was the target of a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 104,000 shares, an increase of 98.9% from the October 31st total of 52,300 shares. Currently, 1.8% of the company’s shares are short sold. Based on an average daily trading volume, of 81,000 shares, the short-interest ratio is currently 1.3 days.

Institutional Trading of Plus Therapeutics

An institutional investor recently bought a new position in Plus Therapeutics stock. AIGH Capital Management LLC acquired a new stake in Plus Therapeutics, Inc. (NASDAQ:PSTV) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned approximately 9.98% of Plus Therapeutics at the end of the most recent quarter. Institutional investors own 3.28% of the company’s stock.

Plus Therapeutics Price Performance

Shares of NASDAQ PSTV traded down $0.02 during mid-day trading on Thursday, hitting $1.26. The company had a trading volume of 12,758 shares, compared to its average volume of 63,761. The company has a market capitalization of $7.43 million, a PE ratio of -0.50 and a beta of 0.69. Plus Therapeutics has a 1-year low of $1.12 and a 1-year high of $2.67. The business’s 50-day simple moving average is $1.36 and its 200 day simple moving average is $1.62.

Wall Street Analyst Weigh In

Several research analysts have recently commented on PSTV shares. HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of Plus Therapeutics in a research report on Tuesday. Ascendiant Capital Markets lowered their price target on Plus Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.